针对蛋白酪氨酸磷酸酶的抗癌药物发现。
Targeting protein tyrosine phosphatases for anticancer drug discovery.
机构信息
Departments of Molecular Oncology and Drug Discovery, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida College of Medicine, Tampa, FL 33612, USA.
出版信息
Curr Pharm Des. 2010 Jun;16(16):1843-62. doi: 10.2174/138161210791209027.
Abstract
Protein tyrosine phosphatases (PTPs) are a diverse family of enzymes encoded by 107 genes in the human genome. Together with protein tyrosine kinases (PTKs), PTPs regulate various cellular activities essential for the initiation and maintenance of malignant phenotypes. While PTK inhibitors are now used routinely for cancer treatment, the PTP inhibitor development field is still in the discovery phase. In this article, the suitability of targeting PTPs for novel anticancer drug discovery is discussed. Examples are presented for PTPs that have been targeted for anticancer drug discovery as well as potential new PTP targets for novel anticancer drug discovery.
摘要
蛋白酪氨酸磷酸酶（PTPs）是一个由人类基因组中的 107 个基因编码的具有多样性的酶家族。PTPs 与蛋白酪氨酸激酶（PTKs）一起调节各种细胞活动，这些活动对于起始和维持恶性表型至关重要。虽然现在已经常规使用 PTK 抑制剂来治疗癌症，但 PTP 抑制剂的开发领域仍处于发现阶段。本文讨论了将 PTP 作为新型抗癌药物发现的靶标的适宜性。本文还介绍了一些已被作为抗癌药物发现的靶标的 PTP 以及一些新的潜在的用于新型抗癌药物发现的 PTP 靶标。
相似文献
1
Targeting protein tyrosine phosphatases for anticancer drug discovery.针对蛋白酪氨酸磷酸酶的抗癌药物发现。
Curr Pharm Des. 2010 Jun;16(16):1843-62. doi: 10.2174/138161210791209027.
2
Targeting SHP-1, 2 and SHIP Pathways: A Novel Strategy for Cancer Treatment?靶向 SHP-1、2 和 SHIP 通路：癌症治疗的新策略？
Oncology. 2018;95(5):257-269. doi: 10.1159/000490106. Epub 2018 Jun 20.
3
Protein-tyrosine phosphatases: structure, mechanism, and inhibitor discovery.蛋白质酪氨酸磷酸酶：结构、作用机制及抑制剂的发现
Biopolymers. 1998;47(3):225-41. doi: 10.1002/(SICI)1097-0282(1998)47:3<225::AID-BIP3>3.0.CO;2-O.
4
Impact of oncogenic protein tyrosine phosphatases in cancer.致癌蛋白酪氨酸磷酸酶在癌症中的作用。
Anticancer Agents Med Chem. 2012 Jan;12(1):4-18. doi: 10.2174/187152012798764741.
5
Targeting PTPs with small molecule inhibitors in cancer treatment.在癌症治疗中使用小分子抑制剂靶向蛋白酪氨酸磷酸酶。
Cancer Metastasis Rev. 2008 Jun;27(2):263-72. doi: 10.1007/s10555-008-9113-3.
6
Drugging the Undruggable: Therapeutic Potential of Targeting Protein Tyrosine Phosphatases.药物研发的困境：靶向蛋白酪氨酸磷酸酶的治疗潜力。
Acc Chem Res. 2017 Jan 17;50(1):122-129. doi: 10.1021/acs.accounts.6b00537. Epub 2016 Dec 15.
7
Functional interrogation and therapeutic targeting of protein tyrosine phosphatases.蛋白质酪氨酸磷酸酶的功能研究与治疗靶向
Biochem Soc Trans. 2021 Aug 27;49(4):1723-1734. doi: 10.1042/BST20201308.
8
Functional studies of protein tyrosine phosphatases with chemical approaches.利用化学方法对蛋白酪氨酸磷酸酶进行功能研究。
Biochim Biophys Acta. 2005 Dec 30;1754(1-2):100-7. doi: 10.1016/j.bbapap.2005.09.005. Epub 2005 Sep 29.
9
Steric hindrance as a basis for structure-based design of selective inhibitors of protein-tyrosine phosphatases.基于空间位阻的蛋白质酪氨酸磷酸酶选择性抑制剂的结构设计基础
Biochemistry. 2001 Dec 11;40(49):14812-20. doi: 10.1021/bi011389l.
10
Nepetin Acts as a Multi-Targeting Inhibitor of Protein Tyrosine Phosphatases Relevant to Insulin Resistance.山奈酚通过抑制与胰岛素抵抗相关的蛋白酪氨酸磷酸酶发挥多靶点作用。
Chem Biodivers. 2022 Jan;19(1):e202100600. doi: 10.1002/cbdv.202100600. Epub 2021 Nov 25.
引用本文的文献
1
Deciphering the structural and dynamic effects of SHP2-E76 mutations: mechanistic insights into oncogenic activation.解析SHP2-E76突变的结构和动态效应：对致癌激活的机制性见解。
BMC Chem. 2025 May 14;19(1):128. doi: 10.1186/s13065-025-01494-2.
2
The phosphatase CTDSPL2 promotes proliferation, invasion, metastasis and regorafenib resistance in osteosarcoma.磷酸酶CTDSPL2促进骨肉瘤的增殖、侵袭、转移和瑞戈非尼耐药。
J Bone Oncol. 2025 Apr 26;52:100684. doi: 10.1016/j.jbo.2025.100684. eCollection 2025 Jun.
3
Targeting Shp2 as a therapeutic strategy for neurodegenerative diseases.将靶向Shp2作为神经退行性疾病的治疗策略。
Transl Psychiatry. 2025 Jan 10;15(1):6. doi: 10.1038/s41398-024-03222-1.
4
EGFR targeting PhosTACs as a dual inhibitory approach reveals differential downstream signaling.EGFR 靶向 PhosTACs 作为一种双重抑制方法揭示了差异化的下游信号转导。
Sci Adv. 2024 Mar 29;10(13):eadj7251. doi: 10.1126/sciadv.adj7251. Epub 2024 Mar 27.
5
Setting sail: Maneuvering SHP2 activity and its effects in cancer.扬帆起航：操纵 SHP2 活性及其在癌症中的作用。
Adv Cancer Res. 2023;160:17-60. doi: 10.1016/bs.acr.2023.03.003. Epub 2023 Apr 17.
6
PROTAC'ing oncoproteins: targeted protein degradation for cancer therapy.靶向蛋白降解技术：用于癌症治疗的靶向蛋白降解。
Mol Cancer. 2023 Mar 30;22(1):62. doi: 10.1186/s12943-022-01707-5.
7
From Stem to Sternum: The Role of Shp2 in the Skeleton.从干细胞到胸骨：Shp2在骨骼中的作用
Calcif Tissue Int. 2023 Apr;112(4):403-421. doi: 10.1007/s00223-022-01042-3. Epub 2022 Nov 24.
8
The Anti-Fungal Activity of Nitropropenyl Benzodioxole (NPBD), a Redox-Thiol Oxidant and Tyrosine Phosphatase Inhibitor.氧化还原硫醇氧化剂及酪氨酸磷酸酶抑制剂硝基丙烯基苯并二恶唑（NPBD）的抗真菌活性
Antibiotics (Basel). 2022 Sep 2;11(9):1188. doi: 10.3390/antibiotics11091188.
9
A comprehensive review of SHP2 and its role in cancer.SHP2 及其在癌症中的作用的全面综述。
Cell Oncol (Dordr). 2022 Oct;45(5):729-753. doi: 10.1007/s13402-022-00698-1. Epub 2022 Sep 6.
10
Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6.双重抑制 MEK 和 CDK4/6 靶向治疗 RAS 突变型结直肠癌。
Cancer Res. 2022 Sep 16;82(18):3335-3344. doi: 10.1158/0008-5472.CAN-22-0198.
本文引用的文献
1
Inhibition of PTP1B by trodusquemine (MSI-1436) causes fat-specific weight loss in diet-induced obese mice.曲格列汀（MSI-1436）抑制 PTP1B 可导致饮食诱导肥胖小鼠的特异性脂肪体重减轻。
Obesity (Silver Spring). 2010 Aug;18(8):1516-23. doi: 10.1038/oby.2009.444. Epub 2010 Jan 14.
2
An anticancer effect of curcumin mediated by down-regulating phosphatase of regenerating liver-3 expression on highly metastatic melanoma cells.姜黄素通过下调再生肝脏-3的表达对高转移性黑色素瘤细胞产生抗癌作用。
Mol Pharmacol. 2009 Dec;76(6):1238-45. doi: 10.1124/mol.109.059105. Epub 2009 Sep 24.
3
Cholinergic agonists regulate JAK2/STAT3 signaling to suppress endothelial cell activation.胆碱能激动剂通过调节JAK2/STAT3信号传导来抑制内皮细胞活化。
Am J Physiol Cell Physiol. 2009 Nov;297(5):C1294-306. doi: 10.1152/ajpcell.00160.2009. Epub 2009 Sep 9.
4
A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide.磷酸酶单倍体不足在来那度胺对5q缺失型骨髓增生异常综合征的选择性抑制中起关键作用。
Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12974-9. doi: 10.1073/pnas.0811267106. Epub 2009 May 26.
5
Activation of Src by protein tyrosine phosphatase 1B Is required for ErbB2 transformation of human breast epithelial cells.蛋白酪氨酸磷酸酶1B对Src的激活是人类乳腺上皮细胞中ErbB2转化所必需的。
Cancer Res. 2009 Jun 1;69(11):4582-8. doi: 10.1158/0008-5472.CAN-08-4001. Epub 2009 May 12.
6
The protein tyrosine phosphatase SHP-2 is required for EGFRvIII oncogenic transformation in human glioblastoma cells.蛋白酪氨酸磷酸酶SHP-2是人类胶质母细胞瘤细胞中EGFRvIII致癌转化所必需的。
Exp Cell Res. 2009 Aug 15;315(14):2343-57. doi: 10.1016/j.yexcr.2009.05.001. Epub 2009 May 8.
7
The therapeutic potential of phosphatase inhibitors.磷酸酶抑制剂的治疗潜力。
Curr Opin Chem Biol. 2009 Jun;13(3):272-83. doi: 10.1016/j.cbpa.2009.03.021. Epub 2009 May 4.
8
Dephosphorylation of the C-terminal tyrosyl residue of the DNA damage-related histone H2A.X is mediated by the protein phosphatase eyes absent.DNA损伤相关组蛋白H2A.X的C末端酪氨酰残基的去磷酸化由蛋白磷酸酶小眼缺失蛋白介导。
J Biol Chem. 2009 Jun 12;284(24):16066-16070. doi: 10.1074/jbc.C900032200. Epub 2009 Apr 7.
9
Expression of phosphatase regenerating liver 3 is an independent prognostic indicator for gastric cancer.磷酸酶再生肝3的表达是胃癌的独立预后指标。
World J Gastroenterol. 2009 Mar 28;15(12):1499-505. doi: 10.3748/wjg.15.1499.
10
Synthesis, activity and molecular modeling of a new series of chromones as low molecular weight protein tyrosine phosphatase inhibitors.新型色酮系列作为低分子量蛋白酪氨酸磷酸酶抑制剂的合成、活性及分子模拟
Bioorg Med Chem. 2009 Apr 1;17(7):2658-72. doi: 10.1016/j.bmc.2009.02.060. Epub 2009 Mar 5.
Zotero 插件